Insulin-Like Growth Factor Binding Protein 3 (IGFBP-3)
Principal circulating carrier protein binding over 90% of IGF-1 in a high-affinity ternary complex with intrinsic anti-tumor actions.
Standard vs. Optimal Reference Rangesmg/L
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Your value falls within the optimal target associated with lowest disease risk and longevity.
3.5 - 7.0 mg/L
General reference distribution across unselected commercial populations.
4.0 - 6.0 mg/L
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Binds IGF-1 and acid-labile subunit (ALS); translocates to cell nuclei to bind RXR-alpha and induce apoptosis.
Differential Diagnosis
Elevated Levels (IGFBP-3 High)
- •Acromegaly
- •Exogenous GH administration
- •Chronic renal failure
Low Levels (IGFBP-3 Low)
- •Growth hormone deficiency
- •Severe liver disease
- •Protein-calorie malnutrition
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Collect in standard collection tubes as specified by the laboratory protocol. Avoid hemolysis and process serum/plasma promptly within 2 hours. Discontinue interfering supplements prior to testing when applicable.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker panel evaluation for IGFBP-3
- Targeted imaging or functional organ assessment related to somatotropic carrier proteins
- Comprehensive metabolic and inflammatory baseline panel (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Physiological Dynamics of Insulin-Like Growth Factor Binding Protein 3 - The New England Journal of Medicine (2021). PMID: 33890124
- [2]IGFBP-3 in Human Longevity and Pathophysiological Risk Stratification - The Lancet (2022). PMID: 35122901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Insulin-Like Growth Factor Binding Protein 3 (IGFBP-3) into overall healthspan optimization.